| 3.82 -0.08 (-2.05%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.9 | 1-year : | 5.39 |
| Resists | First : | 4.2 | Second : | 4.61 |
| Pivot price | 3.81  |
|||
| Supports | First : | 3.52 | Second : | 2.93 |
| MAs | MA(5) : | 3.78 |
MA(20) : | 3.88 |
| MA(100) : | 3.55 |
MA(250) : | 4.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.1 |
D(3) : | 38.9 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 6.96 | Low : | 2.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLNN ] has closed below upper band by 48.0%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.98 - 4.01 | 4.01 - 4.02 |
| Low: | 3.66 - 3.69 | 3.69 - 3.7 |
| Close: | 3.78 - 3.82 | 3.82 - 3.85 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Tue, 08 Jul 2025
Clene (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025 - The Globe and Mail
Mon, 30 Jun 2025
Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs - The Globe and Mail
Mon, 30 Jun 2025
FDA Shows Support for Clene ALS Drug: Biomarker Plan Advances, NDA Filing Expected Late 2025 - Stock Titan
Thu, 08 May 2025
Clene Inc. Advances CNM-Au8 Treatment for ALS, Reports Promising Q1 Results - citybuzz -
Tue, 06 May 2025
Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits - TipRanks
Mon, 14 Apr 2025
Clene to Present at the Emerging Growth Conference - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.14e+006 (%) |
| Held by Institutions | 34.5 (%) |
| Shares Short | 170 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.631e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 32 % |
| Return on Equity (ttm) | -49.7 % |
| Qtrly Rev. Growth | 350000 % |
| Gross Profit (p.s.) | 22.91 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 575000 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.22 |
| Dividend | 0 |
| Forward Dividend | 355530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|